AAAAAA

   
Results: 1-13 |
Results: 13

Authors: Kristoferitsch, W Seeldrayers, P Kyriallis, K Brochet, B Confavreux, C Clanet, M Cesaro, P Defer, G Edan, G Lyon-Caen, O Pelletier, J Rumbach, L Roullet, E Vermersch, P Dengler, R Zschenderlein, R Storch-Hagenlocher, B Sailer, M Hohlfeld, R Kunze, KP Heesen, C Bamborschke, P Grunwald, F Hartung, HP Rieckmann, P DeKeyser, J Montalban, X Fernandez, U Arbizu, T Sandberg, M Kappos, L Bates, D Campbell, MJ Capildeo, R Compston, A McLellan, DL Wroe, S Young, C Clanet, M Hartung, HP Hohlfeld, R Kappos, L Radue, EW Rieckmann, P Sandberg, M Polman, C Kesselring, J Thompson, A Wekerle, H Whitehead, J Bains, H Butler, E Kooijmans-Coutinho, M McAllister, A Simonian, N White, K Anderson, D Liddiard, S Keane, R
Citation: W. Kristoferitsch et al., Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data, MULT SCLER, 7(3), 2001, pp. 179-183

Authors: McDonald, WI Compston, A Edan, G Goodkin, D Hartung, HP Lublin, FD McFarland, HF Paty, DW Polman, CH Reingold, SC Sandberg-Wollheim, M Sibley, W Thompson, A van den Noort, S Weinshenker, BY Wolinsky, JS
Citation: Wi. Mcdonald et al., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis, ANN NEUROL, 50(1), 2001, pp. 121-127

Authors: Comi, G Filippi, M Barkhof, F Durelli, L Edan, G Fernandez, O Hartung, HP Seeldrayers, P Sorensen, PS Rovaris, M Martinelli, V Hommes, OR
Citation: G. Comi et al., Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, LANCET, 357(9268), 2001, pp. 1576-1582

Authors: Edan, G
Citation: G. Edan, Treatment of rapidly worsening multiple sclerosis, REV NEUROL, 157(8-9), 2001, pp. 1008-1013

Authors: Biraben, A Allain, H Scarabin, JM Schuck, S Edan, G
Citation: A. Biraben et al., Exacerbation of juvenile myoclonic epilepsy with lamotrigine - Reply from the authors, NEUROLOGY, 56(10), 2001, pp. 1424-1425

Authors: Blumhardt, LD Vermeij, BJD Amato, M Andersen, O Edan, G Fernandez, O Filippi, M Haas, J Hommes, OR Rieckmann, P
Citation: Ld. Blumhardt et al., A quality network model for the dolly care of multiple sclerosis, MULT SCLER, 6(4), 2000, pp. 231-236

Authors: Edan, G Coustans, M
Citation: G. Edan et M. Coustans, Does immunosuppression constitute a future therapeutic strategy in the treatment of multiple sclerosis?, PATH BIOL, 48(2), 2000, pp. 114-120

Authors: de Seze, J Edan, G Labalette, M Dessaint, JP Vermersch, P
Citation: J. De Seze et al., Effect of glatiramer acetate (Copaxone) given orally in human patients: Interleukin-10 production during a phase 1 trial, ANN NEUROL, 47(5), 2000, pp. 686-686

Authors: Reboul, J Mertens, C Levillayer, F Eichenbaum-Voline, S Vilkoren, T Cournu, I Babron, MC Lyon-Caen, O Clerget-Darpoux, F Edan, G Clanet, M Brahic, M Bureau, JF Fontaine, B Liblau, R
Citation: J. Reboul et al., Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach, J NEUROIMM, 102(1), 2000, pp. 107-112

Authors: Drapier, S Kassiotis, P Mourtada, I Pinel, JF Edan, G
Citation: S. Drapier et al., Multiple strokes with livedo after anti-cancer therapy with Interleukin-2 and Interferon alpha, REV NEUROL, 156(10), 2000, pp. 901-903

Authors: Biraben, A Allain, H Scarabin, JM Schuck, S Edan, G
Citation: A. Biraben et al., Exacerbation of juvenile myoclonic epilepsy with lamotrigine, NEUROLOGY, 55(11), 2000, pp. 1758-1758

Authors: Brassat, D Azais-Vuillemin, C Yaouanq, J Semana, G Reboul, J Cournu, I Mertens, C Edan, G Lyon-Caen, O Clanet, C Fontaine, B
Citation: D. Brassat et al., Familial factors influence disability in MS multiplex families, NEUROLOGY, 52(8), 1999, pp. 1632-1636

Authors: Edan, G
Citation: G. Edan, New therapeutic strategies for multiple sclerosis: unanswered questions, REV NEUROL, 154(12), 1998, pp. 813-815
Risultati: 1-13 |